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Abstract 
To estimate a rate of spread of ESBL-producing Enterobacteriaceae among out and inpatient Sabha Medical 
Center in stool, urine samples.  ESBLS activities were tested by the double disk synergy. The isolates were 
Escherichia coli 83(47.7%), 42(24.13%), Klebsiella spp. 21(12.0%), 11(6.3%), other type of 
Enterobacteriaceae 13(7.4%) 4(2.29%) for in and outpatient respectively. Forty four (25.28%) ESBLs strains 
were detected in 54.5%, 11.36% of E. coli, 15.9%, 4.5% of Klebsiella spp., 11.36%, 2.27%of other, for in and 
outpatient respectively. Prevalence rates 22.72%, 13.6%, 11.36 %, 9.09 % , 6.81% , 6.81 %,4.5% , 4.5% , 2.27% 
of ESBLs were isolated from patients on the Nursery, Medicine, surgery , Pediatric, Urology, Obstetric, Kidney 
Ward, ICU and ophthalmic department respectively. Fecal carriage of ESBLs is 34% 6.8% for in and outpatient. 
Our study has provided a first ESBLS screening for Enterobacteriaceae in Sabha Medical Center. Faecal 
ESBLS-producing Enterobacteriaceae for   inpatient is referring to the weakly antimicrobial policy 
implemented in the hospital and the aware risk of the spread it in the community. ESBLS- E. infection is 
prominent in Urinary Tract Infection for Nursery department and seems demonstrates the outbreak state in the 
hospital. 
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1. Introduction  
Extended-spectrum beta-lactamases (ESBLS) were term used to indicate enzymes that able to resistance 
penicillin, the first, second and third generation cephalosporins which extended to monobactam. These enzymes 
are broken the beta-lactam ring causes inactivating the antibiotic. The first ESBLS described were in Greece in 
the 1960s and named TEM [1]. TEM was present on plasmid of gram negative bacteria; also other enzymes 
discovered were related to it. The most common ESBLS are in Enterobacteriaceae especially E.coli in Europe 
and other regions [2]. Other types of ESBLS are associated with a variety of mobile genetic elements on 
chromosome [3]. 
The worldwide prevalence of ESBLS among Enterobacteriaceae is a major note in both hospital nosocomial 
infection and community acquired infection [4]. On the other hand, these enzymes are causes multi resistant 
bacteria to other antibiotic options remain available [5]. ESBLS are the big challenges for antibiotic treatment in 
the last and present years [6], which increase especially by using the empirical management of community-
associated infection [2]. The risk of increased antimicrobial resistance in the future is happen by development of 
ESBLS types which causes treatment difficulty year by year [ 4, 5, 3, 7] . Furthermore, ESBL testing is must be 
used as diagnostic test in hospital to avoid using the β-lactam antibiotics treatment and also useful for 
epidemiological purposes [8]. 
2. Objective 
The studies on the prevalence of ESBLS in the outpatient especially in the feces carrier Enterobacteriaceae are 
little known in the Libya. Therefore, the aim was to estimate the rate of spread of ESBL-producing 
Enterobacteriaceae in outpatient and inpatient Sabha Medical Center Hospital (Libya) in stool and urine 
samples. 
3. Methodology 
3.1. Samples of patients 
A total of 174 urine and stool samples were collected from out and in patent attending Sabha medical center. 
The study was carried out between June 2013 to Feb 2014, Sabha city, Libya. All sample were collected under- 
standard condition in this hospital. 
3.2. Isolation and Identification 
By using the standard loops, the urine samples were cultured on MacConky and blood agar plate. The stool 
samples were cultured on MacConky agar and Sallmonella-Shigell agar. All cultures were incubated at 37C° for 
18-24 hours. The positive urine cultures were more than 105CFU/ml. Isolated colonies from significant plate 
were identified by using APIE20 system (Bio Me'rieux sa, 69280 Marcy I`Etoile-France) and the test performed 
according to the manufacture. Reference strain of E.coli ATCC 25922 was used as control in this study. 
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3.3. Sensitivity test 
3.3.1. Preparation of bacterial inoculum 
The inoculum was prepared by selecting a number of colonies from 18 hours cultured plate on a nutrient agar. 
The colonies were then emulsified into sterile normal saline. The turbidity of inoculum was adjusted to that of 
0.5 McFarland [9]. 
3.3.2 The disk diffusion test  
The antibiotic susceptibility testing was performed by the disk diffusion method according to the NCCLs 
recommendation M100-S25 [9]. Briefly, within 15 minute the adjusting suspension was streaked by the swab 
over the Muller-Hinton agar surface, the antibiotic disk dispensed onto the surface of the inoculated agar with 
no closer than 24mm from center to center. E.coli ATCC 25922 was used for each test run. All the plates were 
incubated at 35C° for 18 hours. 
3.3.3. Double Disk synergy (ESBLS Detection) 
This test was performed according to the technique reported by Monald and Thompson [10]. A single separated 
colony from an overnight blood agar culture was emulsified in 0.9% normal saline solution tube. The turbidity 
of suspension was adjusted to give 0.5% McFarland standard. The suspension was spread on Muller-Hinton agar 
plate by the sterile cotton swab. The disks containing the standard 30mg ceftazidium, ceftriaxone, cefotaxime 
and aztreonam were placed at 25mm a center to center from amoxicillin/clavulanic acid 20/10mg. The plates 
were incubated at 35C° to 18 hours. 
3.4. Statistical analysis. 
The statistical significance of difference between categorical variables was evaluated by T-test and Fisher Test.   
Significance was accepted when P= ≤ 0.05.  The statistical analysis of the data carried out by using Minitab 
program 16. 
4. Result 
4.1. The types of bacterial isolates 
In this study 174 strains were isolated from urine and stool samples which contained different type of bacteria, 
E.coli, Klebsiella spp., other type of Enterobacteriaceae from inpatient and outpatient isolates as showed in the 
Table (1).  Distribution of E. coli, Klebsiella spp., and bacteria isolated from in patients stool and urine samples 
according to type of bacteria; sample and hospital department is shown in Figure (1). 
4.2. Sensitivity test 
The Enterobacteriaceae collections were tested for antimicrobial susceptibility by Kirby-Bauer disk diffusion 
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method and Double Disk synergy. The antibiotic tested against  E.coli for inpatient and outpatient were resistant 
by 20.8%,3.2% to cefotaxime ,  16.8% , 5.6% to ceftriaxone, 8.8%, 10.4% to ceftazidium , 20.8% , 12.8% to 
aztreonam , 14.4%, 8.8% to amoxillin/clavulanic acid , 40.8% , 16% to cefoxitin, 28%, 16.8% to cephalothin, 
and 56.8%, 26.4% to ampicillin(Figure 2).  
Table (1) The types of bacterial isolates in this study. 
Bacteria isolates Inpatient No. (%)    Outpatient No. (%) 
    
E.coli                      83(47.7)  42(24.13) 
Klebsiella spp.         21(12.0)  11(6.3) 
Other                 13(7.4)  4(2.29) 
Total                    117            57 
Other= other type of   Enterobacteriaceae 
 
 
Figure 1:  The sources and Bacterial isolates % form Hospital department types. 
The Klebsiella spp. for inpatient and outpatient were resistant by 12.9%, 9.6% to cefotaxime ,  9.6% , 3.2% to 
ceftriaxone, 12.9%, 6.4% to ceftazidium ,19.3%,6.4% to aztreonam  6.4%, 0 % to amoxillin/clavulanic acid , 
45.16% , 12.9% to cefoxitin, 19.3%, 9.6 % to cephalothin, and 54.8%, 19.3% to ampicillin (Figure 3).  
 Other type of  Enterobacteriaceae for inpatient and outpatient were resistant by 25%, 0% to cefotaxime and 
ceftriaxone, 31.25%, 6.25% to ceftazidium ,37.5%,6.25% to aztreonam  18.5%, 6.25 % to amoxillin/clavulanic 
acid , 62.5% , 18.7% to cefoxitin, 62.5%, 12.5 % to cephalothin, and 87.5%, 18.7% to ampicillin (Figure 4). 
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Statistically significant different was between inpatient and outpatient isolates P<0.05, P=0.05 for both E.coli, 
other type and Klebsiella spp. respectively. 
.  
Figure 2:  Antibiotic susceptibility test   (resistant %) for E.coli P<0.05. 
 
Figure 3: Antibiotic susceptibility test   (resistant %) for Klebsiella spp. P=0.05. 
 
Figure 4: Antibiotic susceptibility test (resistant %) for other type of  Enterobacteriaceae isolates P<0.05. 
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4.3. Double Disk synergy (ESBLS Detection) 
ESBLs strains were detected in all isolates for inpatient and outpatient as shown in the table (2). Only 8 (4.59%) 
ESBLS strains were for outpatient. Of the 36 (20.68%) clinical isolates were for inpatient ESBLS 
Enterobacteriaceae. Of the Nursery department were 9 E. coli, 1 Klebsiella spp. (70% from   urine),  in 
Medicine Ward 5 E. coli, 1 other types of Enterobacteriaceae (50% form stool and urine), in surgery ward 3 E. 
coli, 2 Klebsiella spp. (60% from stool) and Pediatric Ward 3 E. coli, 1 Klebsiella spp.   (75% from stool 
sample). Where were for Urology department 2 E. coli, 1 other types (66% from stool), and for Obstetric Ward 
3 E. coli (100% from urine). On the other hand, in the  Kidney Ward and ICU were 1 E. coli, 1 Klebsiella spp,  
and 2 E. coli (100% from stool) (100% from urine) respectively, then ophthalmic department (100% stool) (5). 
Table (2) ESBL production percentage in bacterial isolates types. 
Inpatient 
No. (%)                                                                                          
                                                            Outpatient 
No. (%) 
E.coli  24(54.5)‡ E.coli   5(11.36) ‡ 
Klebsiella spp. 7(15.9) ‡ Klebsiella spp.   2(4.5) ‡ 
Other  5(11.36) Other    1(2.27) 
Stool 15(34) ⃰ 
Urine 21(47.7) ⃰                                               
                                                             Stool 3(6.8) ⃰ 
                                                         Urine5(11.36) ⃰ 
                    Total ESBL No. (%)   =     44 (25.28) 
ESBLS  stool samples =     18  (40. 9)  
     ESBLS urine samples =    26 (59.09) 
 
          ‡=Fisher Test P > 0.05, ⃰ = Fisher Test P>0.05 
5. Discussion 
The Enterobacteriaceae collections were become resistant to our usual antibiotics by acquiring genes encoding 
enzymes that destroy important antibiotics, this demonstrated in the results which increased resistant to 
Penicillin and then the first generation of Cephalosporin (Figure 2. 3. 4), while recession resistant to the 
Monobactam then third generation of Cephalosporin to both inpatient and outpatient   [11] with statistical 
different significantly (P<0.05). The Ampicillin resistant were higher than recorded in our results by both 
Abujnah A. A.  and his colleagues [11] and Ghenghes K. S.  and his colleagues [12]. The third generation 
Cephalosporin has been used in the recent years [11].   
Generally, our study was detected of ESBLS, for inpatient and outpatient in the Sabha Medical Center Hospital. 
ESBLS positive rate is higher than that reported in Zawiya Teaching Hospital [11]. When compared the results 
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with the other hospitals in Arabic area like in Algerian hospitals, ESBLs are detected around 16.4-31.4% of the 
clinical samples, In Egypt, ESBLs were found in 11-42.9% of samples in both hospitals and among the 
community [13]. In Tunisia, ESBLs, pAmpC, and carbapenemases were present and the spreading ranges from 
11.7 to 77.8% in city hospitals and were 0.7 and 7.3% in two communities [14]. Normally, the results are 
different by increase the number of hospitals under study. The results showed that the ESBL-producing isolates 
were highly inpatient isolates than outpatient, that the reversed results which reported by Abujnah A. A.  and his 
colleagues [11]. Non  statistical significant difference were between ESBLS-  producing by both E. coli or 
Klebsiella spp. and types of patients category (P>0.05). 
 
Figure 5: ESBL production percentage in Hospital departments types P<0.05. 
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isolates distributed results in other hospital departments were lower than reported abroad [16]. The statistical 
different significantly were between hospital department results (P<0.05). 
Generally, the present proportion of ESBLS products in our samples is not surprising because the country has an 
excess of antibiotic used [11]. On the other side, the observed ESBLS-producing Enterobacteriaceae in hospital 
fecal samples is lower than that reported in the other study [17, 18, 19]. The faecal ESBLS-producing 
Enterobacteriaceae among inpatient was higher than outpatient. Non statistical significant difference were 
between samples ESBLS- producing types (stool or urine) and types of patients category (P>0.05). However the 
presence of ESBLS among faecal E. coli in Libya confirms its pervasiveness in the community and raises 
concern regarding this highly virulent and resistant clone. Finally, the results showed that the ESBL-producing 
isolates were highly for E. coli than Klebsiella spp. which in agreement with Hilty M. and his colleagues [20] 
and no with other reported [11]. 
6. Conclusion 
Our study has provided a first ESBLS screening for Enterobacteriaceae in Sabha Medical Center. The findings 
of this study showed that E. coli and Klebsiella spp. were the predominant our strains and ESBL-producing 
isolates highly in E. coli strains. The present of faecal ESBLS-producing Enterobacteriaceae for   inpatient is 
referring to the weakly antimicrobial policy implemented in the hospital and the aware risk of the spread it in the 
community. On the other hand, the laboratories should be aware of the implications of modified drug 
susceptibility testing reports on antibiotic prescription policies. Furthermore, ESBL E. coli infection is 
prominent in UTI for Nursery department and seems demonstrates the outbreak state in the hospital. 
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